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Introduction
The HIV-1 Virion Infectivity Factor (Vif) is a small basic protein 
of 192 amino acids (23 KDa, pI = 10.7). It has been known for 
a long time to be essential for viral replication in some, but not 
all, cell lines.1-5 In absence of Vif, human antiviral proteins from 
the APOBEC3 cytidine deaminase family are packaged into viri-
ons and exhibit anti-HIV-1 activity mostly by two mechanisms: 
(1) deamination of cytidines in the minus strand of the proviral 
DNA,6-8 and (2) inhibition of the reverse transcription through 
a deaminase-independent mechanism.9-11 APOBEC3G, formerly 
known as CEM15, was first identified as a potent endogenous 
inhibitor for replication of several retroviruses, including HIV-
1.8,12,13 Later on, other members of the APOBEC3 family have 
been identified as HIV-1 restriction factors: APOBEC3F,12,14,15 
APOBEC3B,12,16 APOBEC3DE17 and APOBEC3H.18 The anti-
retroviral activity of APOBEC3DE19 and APOBEC3H17,20 is how-
ever still controversial and, with the exception of APOBEC3F, 
these proteins are poorly expressed in human lymphoid tissues 
and only lead to a moderate effect on HIV-1 infection.
To bypass the host defense system and counteract APOBEC3 
action, Vif dramatically reduces APOBEC3G incorporation 
into the virion using several pathways (for a review on 
The hIV-1 Vif protein plays an essential role in the regulation of the infectivity of hIV-1 virion and in vivo pathogenesis. Vif 
neutralizes the human DNA-editing enzyme ApOBec3 protein, an antiretroviral cellular factor from the innate immune 
system, allowing the virus to escape the host defense system. It was shown that Vif is packaged into viral particles through 
specific interactions with the viral genomic RNA. conserved and structured sequences from the 5’-noncoding region, 
such as the Tat-responsive element (TAR) or the genomic RNA dimerization initiation site (DIs), are primary binding sites 
for Vif. In the present study we used isothermal titration calorimetry to investigate sequence and structure determinants 
important for Vif binding to short viral RNA corresponding to TAR and DIs stem-loops. We showed that Vif specifically 
binds TAR and DIs in the low nanomolar range. In addition, Vif primarily binds the TAR UcU bulge, but not the apical loop. 
Determinants for Vif binding to the DIs loop-loop complex are likely more complex and involve the self-complementary 
loop together with the upper part of the stem. These results suggest that Tat-TAR inhibitors or DIs small molecule binders 
might be also effective to disturb Vif-TAR and Vif-DIs binding in order to reduce Vif packaging into virions.
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Vif-APOBEC3 interactions see refs. 21–23). First, Vif interacts 
with APOBEC3F/G and hijacks the human E3 ubiquitin ligase 
complex consisting of Cullin5, ElonginB, ElonginC and a zinc 
RING finger protein (Rbx), leading to a polyubiquitination of 
APOBEC3F/G and to its degradation by the 26 S proteasome.24-28 
It was recently shown that, in addition to the E3 ubiquitin ligase 
complex, the transcription cofactor CBF-β is also recruited 
by Vif and is required for the APOBEC3G degradation.29-31 
Interestingly, APOBEC3B16 and APOBEC3H18 have been 
reported to escape this Vif-mediated degradation. Besides 
APOBEC3 degradation, Vif negatively regulates APOBEC3G 
transcription through binding to 5'-UTR of APOBEC3G 
mRNA.28,32,33 Finally, Vif also reduces APOBEC3G packaging 
into the virion by competing for the same Gag and viral RNA 
binding sites, thus leading to a physical exclusion of APOBEC3G 
from the budding virion.27,32,34,35 It was indeed shown by several 
studies that Vif is an RNA-binding protein that specifically 
recognizes the viral RNA in vitro and in infected cells.36-39
Several conserved domains have been identified in Vif:40 (1) 
a tryptophan-rich N-terminal domain responsible for RNA and 
APOBEC3 binding, (2) a HCCH motif that coordinates a Zn2+ 
ion and which is responsible for the binding with Cullin5, (3) 
an 144SLQ(Y/F)LA149 motif, named “SOCS-box”, responsible 
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yielded 20% α-helix, 26% β-strands, 23% turns and 30% of 
disordered structure (which was expected in the Gag/Membrane 
and Elongin B/C binding domains in absence of their partners), 
with good agreement between calculated and experimental data 
(Fig. 2A). This result shows that the produced protein is correctly 
folded after denaturation/renaturation and observed secondary 
structure is approximately in agreement with recently published 
Vif CD data.42,49,52 However, a significant increase in α-helix and 
decrease in β-strands contents is noticeable compared with previ-
ous reports (Table 1). This difference might be responsible for 
the increased solubility of our Vif sample, in line with a previous 
study showing that formation of β-sheets might be responsible 
for Vif aggregates.53
We next analyzed the homogeneity of Vif using Dynamic 
Light Scattering (DLS) to ensure that our sample was monodis-
perse and free of aggregates, two necessary conditions required 
for reliable and good quality ITC analysis. Based on DLS mea-
surements performed at various protein concentrations (4 to 200 
μM), we found that the protein sample was highly monodisperse 
with a polydispersity index of 16.3% and a hydrodynamic radius 
of 7 nm (Fig. 2B). This is in good agreement with the recent 
report of Bernacchi et al.42 but quite different from Gallerano et 
al. who obtained a hydrodynamic radius of 24 nm with a poly-
dispersity index of 51%. Our DLS measurements performed at 
10%, 5% and 2.5% glycerol concentrations did not show any 
significant variations down to 2.5% of glycerol, whereas massive 
aggregation was observed in absence of glycerol (not shown). 
To investigate the oligomerization state of our Vif construct, 
the average molecular weight of the sample was evaluated using 
Static Light Scattering (SLS). In a buffer containing 5% glyc-
erol, we observed an average molecular weight of 270 kDa, which 
corresponds to multimers containing 10 to 11 Vif proteins and 
is in agreement with a recent similar study based on both size 
exclusion chromatography and DLS.42 We concluded from these 
experiments that, even in absence of the co-factor CBF-β, the 
produced wild-type Vif protein can be obtained under a soluble, 
homogenous and stable form at concentrations up to 400 μM, 
and is therefore suitable for ITC measurements.
Vif binding to HIV-1 TAR RNA stem-loop. In a further step, 
isothermal titration calorimetry (ITC) was used to characterize 
Vif binding to the TAR stem-loop. ITC is a true in-solution tech-
nique and is considered the “gold standard” assay for binding 
since it directly provides, in one single experiment, the complete 
binding profile between two molecules, without any labeling 
requirement (reviewed in ref. 54–56). Typically, the ligand solu-
tion is repetitively injected in small aliquots from an automatic 
syringe into a thermally isolated stirred cell containing the pro-
tein. In an ITC experiment, one physically measures the heat 
generated or absorbed during a binding reaction. A direct mea-
surement of the binding thermodynamics allows determination 
of the binding affinity (K
a
), enthalpy and entropy changes (ΔH 
and ΔS) and stoichiometry (N) between two molecules.
Several Vif aliquots (1.5 to 2.0 μl at a ~200 μM concentra-
tion) were injected into 15 μM TAR RNA. This protocol was 
used since the reverse titration (injections of concentrated TAR 
aliquots into diluted Vif protein) systematically led to aggregation 
for the interaction with Elongin B/C, (4) a proline-rich region 
containing a 161PPLP164 motif involved into Vif multimerization 
and (5) a C-terminal domain interacting with Gag and the 
cellular membrane (Fig. 1A).
Using RNase-T1 footprinting, an enzyme that cleaves after 
a guanine residue accessible to solvent, preferential Vif RNA 
binding sites have been mapped in the 5'-region of the genomic 
RNA.37,41 The strongest affinity was observed for the apical part 
of the TAR stem-loop, the poly(A) stem and a short region in 
gag, whereas the primer-binding site (PBS), the SL1 and SL2 
stem-loops, as well as a purine-rich single-stranded region adja-
cent to the Gag start codon have been identified as lower-affinity 
Vif-binding sites.37 Binding to the upper part of the TAR stem-
loop was subsequently confirmed on short RNA fragments using 
steady-state fluorescence spectroscopy.41,42
In the present work, we used Isothermal Titration Calorimetry 
(ITC) to study the binding thermodynamics of Vif binding to 
the HIV-1 genomic RNA TAR and Dimerization Initiation Site 
(DIS) stem-loops (Fig. 1B). Using various mutants of TAR and 
DIS mutants (Fig. 1C), we could define the sequence and struc-
ture requirements for the Vif specific binding to these regions of 
the viral RNA. Our results show that Vif specifically and tightly 
binds both TAR and DIS sequences in the low nanomolar range. 
Vif primarily binds the UCU lateral bulge of the TAR, and sec-
ondarily the apical loop. Regarding binding to the DIS loop-loop 
complex, we found that mutations of the DIS loop preventing 
DIS dimerization also affect Vif binding, whereas the purine-
rich internal loop of the DIS stem is clearly dispensable. Our 
data also indicate that the upper part of the DIS stem might be 
important for protein binding. Taken together, these results open 
the perspective of developing drugs that would prevent Vif bind-
ing to the TAR and DIS stem-loops and, consequently, reduce 
Vif packaging. They also suggest that Vif might compete with 
APOBEC3G for binding the DIS stem-loop, leading to an exclu-
sion of the restriction factor from the viral particle.
Results
Biophysical characterization of the full-length HIV-1 Vif pro-
tein. It has been shown that Vif monomers self-associate into 
multimers both in vitro and in infected cells.43,44 The 161PPLP164 
motif is important for this Vif oligomerization, for viral infec-
tivity,42,45-47 and was also reported to interact with Elongin B.48 
Mutation of the PPLP motif into AALA reduces, but does not 
abolish, oligomerization.42 This strong tendency of Vif to self-
associate and aggregate33,42,49,50 has also thwarted attempts to 
obtain large quantities of high-quality and homogenous pro-
tein. Here, we successfully expressed and purified milligrams of 
recombinant full-length wild-type Vif, typically about 13 mg of 
purified protein per liter of cell culture, thus allowing detailed 
ITC analysis of Vif/RNA interaction. Because the recombi-
nant protein was always found insoluble when expressed in E. 
coli,33,41,42,49-51 Vif was solubilized using guanidine hydrochlo-
ride and subsequently refolded by dialysis. The proper folding 
of the protein was assessed using far-UV circular dichroism 
(CD). Secondary structure calculations from the CD spectra 
©
20
12
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
968 RNA Biology Volume 9 Issue 7
Figure 1. (A) schematic representation of identified Vif functional regions. (B) secondary structure of the 5’-untranslated region of the hIV-1 RNA 
genome. (c) RNA sequences used in this study.
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obtained at 25°C, providing access to a temperature dependence 
of the binding enthalpy (see Sup. data). In our experimen-
tal conditions and in presence of 200 mM KCl, we observed a 
specific Vif binding to the TAR27 RNA (Figs. 1C and 3). The 
of the protein/RNA complex in the ITC cell as judged by an 
abnormally high exothermic signal and baseline drift. In addi-
tion, most of our data were acquired at 30°C since baselines were 
more stable at this temperature. Some data were nevertheless 
Figure 2. Biophysical characterization of purified Vif protein. (A) Far-UV spectra of the Vif protein and reconstructed data. (B) Dynamic light scattering 
profiles of the hIV-1 Vif showing a mean diameter of 14 nm.
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reinforced by subsequent (mostly electrostatic) interactions with 
the TAR apical loop.
Vif binding to HIV-1 DIS RNA kissing-loop. We next 
investigated the Vif binding to the DIS stem-loop. Because of 
the self-complementarity in the loop, the wild-type 35-mer DIS 
monomer forms DIS loop-loop dimers (also called kissing-loop) 
in native conditions (reviewed in refs. 57 and 58). Alternatively, 
an extended duplex dimeric form can also be obtained in vitro 
depending on RNA folding conditions. In this study, care was 
taken to use folding conditions leading essentially to DIS loop-
loop complexes (see materiel and methods). To define RNA 
determinants for the protein binding, two mutants were designed 
(Fig. 1C): (1) the DIS-Δ mutant, where the internal purine-rich 
loop was deleted. It was shown that this internal loop is important 
for viral infectivity59 and might be involved into binding of 
the NCp7 nucleocapsid protein;60 (2) the DIS-GAGA mutant 
containing a GAGA tetraloop instead of the nine nucleotide 
apical loop. As a consequence for this mutation, the DIS-GAGA 
mutant was not able to form dimers in vitro in our conditions as 
evaluated by native polyacrylamide gels (not shown).
ITC data performed in presence of 200 mM KCl on the wild-
type DIS 35-mer showed that Vif specifically and tightly (K
d
 = 63 
nM) binds the DIS loop-loop complex with a 1:1 stoichiometry 
(one Vif binding per DIS stem-loop monomer, Fig. 5 and 
Table 2). As seen previously for TAR binding, the Vif/DIS 
interaction is exothermic and mostly driven by enthalpic 
contributions (ΔH = -9.1 kcal/mol, -TΔS = -0.9 kcal/mol). An 
increase of the monovalent salt concentration to 300 mM KCl 
led to a 2.8-fold loss in affinity (K
d
 = 177 nM) but still preserved 
the specificity of the interaction (n = 0.8). Deletion of the purine-
rich internal loop of the DIS (sequence DIS-Δ, Fig. 1C) does 
not significantly affects Vif binding, neither in 200 mM KCl, 
nor in 300 mM KCl. The affinity of Vif for this DIS mutant 
only drops about 1.2-fold compared with the wild-type DIS 
and the stoichiometry remains close to 1:1 (Fig. 5 and Table 
2). As seen previously for the TAR-GAGA mutant, a loss in the 
negative binding enthalpy is compensated by a positive entropic 
contribution for this DIS-Δ sequence. Experiments performed on 
the DIS-GAGA sequence revealed more significant differences 
in Vif binding. In conditions based on 200 mM KCl, a 2-fold 
loss in affinity was observed. In higher salt concentration, it was 
not possible to properly fit ITC corrected injection heats using 
a single site binding model used for all other ITC data (Fig. 5), 
suggesting a more complex protein binding.
observed dissociation constant (K
d
 ~ 160 nM) is associated with 
a rather large negative enthalpy variation (ΔH = -10.6 kcal/mol, 
corresponding to an exothermic process) and a slightly negative 
entropy variation (Fig. 3 and Table 2). The specificity of the 
protein/RNA binding is assessed by the 1:1 observed stoichiom-
etry. This implies either that each Vif protein within a multi-
mer is able to bind independently one TAR RNA, or that Vif 
multimers dissociate upon TAR binding. In a previous report 
it was found that, upon Vif binding to short RNA constructs, 
the mean hydrodynamic radius of resulting Vif/RNA complexes 
significantly increased compared with the free protein.42 This 
observation therefore suggests that RNA binding does not pro-
mote Vif multimer dissociation. An increase of monovalent salt 
concentration to 300 mM, in order to reduce potential unspe-
cific electrostatic Vif/RNA interactions, only led to a moderate 
decrease of the dissociation constant (1.8-fold). This suggests a 
significant contribution of hydrophobic interactions in the Vif/
TAR interaction, likely through the tryptophan-rich RNA bind-
ing region (Trp5, Trp11, Trp21, Trp38, Trp79 and Trp89).
To further confirm the specificity of the Vif/TAR interaction, 
we used the E. coli 23 S RNA sarcin-ricin loop (SRL), a highly 
structured RNA stem-loop similar in size, but unrelated to TAR 
(Fig. 1C), as a control for unspecific RNA binding. Mixing of 
Vif into SRL RNA only led to a weak endothermic signal (ΔH = 
~5.0 kcal/mol), that could not be fitted using a single site binding 
model (Fig. 4 and left). Furthermore, increasing the salt concen-
tration to 300 mM led to a complete loss of interaction (Fig. 4 
and right).
In order to define structure and sequence determinants for 
Vif binding to TAR RNA, we next used two TAR mutants 
(Fig. 1C): TAR-GAGA, where the wild-type five nucleotide 
apical loop was replaced by a GAGA tetraloop (a member of 
thermostable GNRA tetraloops), and TAR-ΔUCU, where the 
apical three nucleotide lateral bulge was deleted (Fig. 1C). ITC 
data obtained on the TAR-GAGA (in 200 mM KCl) mutant 
did not reveal any significant change in Vif binding. The 
observed stoichiometry (n = 0.7) was still close to 1.0 and both 
the dissociation constant (1.2-fold decrease) and the enthalpy 
variation (ΔH = -8.9 kcal/mol) were only moderately affected 
(Fig. 3 and Table 2). Notably, the small decrease in the enthalpic 
component is compensated by a slightly positive entropic term. 
Likewise, the protein binding to this mutant TAR sequence was 
only poorly affected in a buffer containing 300 mM KCl: the 
affinity decreased ~2-fold compared with binding to the TAR27 
in the same conditions, together with a slight decrease of ΔH 
(Fig. 3 and Table 2).
On the contrary to the mutation of the apical loop, deletion of 
the UCU lateral bulge severely affected Vif binding as revealed by 
ITC data obtained with the TAR-ΔUCU sequence. In conditions 
with 200 mM KCl, the stoichiometry significantly increases to 
n = 2.0 and the K
d
 decreased to about 1 μM, which represents a 
6.7-fold loss compared with wild-type sequence. In a buffer with 
300 mM KCl, no Vif binding could be detected anymore (Fig. 
3 and Table 2). We conclude from this set of experiments that 
Vif likely binds primarily the UCU lateral bulge of TAR through 
specific hydrophobic interactions. This interaction might be 
Table 1. comparison of Vif secondary structure composition derived 
from cD data
Reference α-helix β-strands turns disordered
33 6.5% 41.5% 12% 40%
49 11% 33% 28% 28%
52 6% 32% 62%
This work 20% 26% 23% 30%
Our data and those from references 33 and 49 were obtained using the 
same cDssTR algorithm and reference set database, thus ruling out any 
influence of the data processing.
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Figure 3. ITc profiles for the titration of hIV-1 Vif on the hIV-1 TAR27 stem-loop and mutant TAR sequences at 30°c and in presence of 200 or 300 mM 
of Kcl. each heat burst curve is the result of a 1.5 or 2.0 μl injection of 200 μM Vif in a 15 μM RNA solution. The corrected injection heats were derived 
by integration of the ITc profiles and were fitted with a one site binding model. “n.a.” denotes “not applicable” since no binding was observed.
Table 2. summary of binding parameters derived from ITc measurements for Vif binding to hIV-1 TAR and DIs wild-type and mutant sequences
200 mM KCl 
300 mM KCl
DIS-WT DIS-Δ
DIS-
GAGA
TAR-WT
TAR-
GAGA
TAR-
ΔUCU
N 1.1 0.8 1.0 0.7 1.1 n.d. 0.8 0.9 0.7 1.4 2.0 n.d.
ΔH (kcal/mol) -9.1 ± 0.1 7.1 ± 0.1
-8.0 ± 
0.1
-5.9 ± 0.1
-7.1 ± 
0.1
n.d.
-10.6 ± 
0.2
-8.4 ± 0.1
-8.9 ± 
0.1
-7.1 ± 0.2
-7.2 ± 
0.2
n.d.
ΔS (cal/mol/deg) 2.9 7.4 6.3 11.0 8.3 n.d. -3.8 2.2 1.3 5.2 3.5 n.d.
Kd (nM) 63 ± 3 177 ± 21 75 ± 9 229 ± 16
121 ± 
10
n.d. 159 ± 20 286 ± 22 198 ± 13 606 ± 81
1070 ± 
122
n.d.
N.d. denotes “not determinable” since accurate values could not be obtained.
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affecting the loop-loop complex integrity but preserving the 
7-base-pair stem (Fig. 5 and Table 2). As a consequence, Vif 
likely binds the DIS kissing-loop mostly through hydrophobic 
interactions and the 7-base-pair stem through electrostatic inter-
actions. Because A272 and G273 are observed in an extrahelical 
conformation in crystal structures of the DIS kissing-loop com-
plex,61,62 we can hypothesize that they are involved into stacking 
interactions with some Vif tryptophan residues. Furthermore, 
because of structural similarities between the DIS kissing-loop 
complex and DIS extended duplex forms,63,64 which is putatively 
present in mature virions and obtained after isomerization by the 
NCp7 protein,65,66 we can anticipate that Vif should also specifi-
cally interact with this form of the DIS dimer.
Discussion
Here we show using Isothermal Titration Calorimetry that Vif 
specifically binds HIV-1 TAR stem-loop and DIS kissing-loop 
complex. Using a set of TAR and DIS mutants, we elucidated 
RNA determinants of Vif interaction to both sequences.
We found that Vif primarily recognizes the TAR UCU lateral 
bulge, which appears to be essential for the protein binding. The 
TAR apical loop might play a secondary role in the Vif binding 
since it contributes positively, but moderately, to the interaction. 
Interestingly, it is well-established that the TAR UCU lateral 
bulge is recognized by an arginine-rich RNA-binding motif 
of the HIV-1 Tat protein,67,68 another small regulatory basic 
protein. This Tat/TAR interaction is essential for Tat-dependent 
transcriptional activation.69 Several low molecular-weight 
In order to understand the role of the DIS 
loop dimerization in Vif binding, we tested 
the protein interaction on a DIS loop mutant 
with a U275C mutation that prevents self-
dimerization (sequence DIS 23 U275C, Fig. 
1C). In addition, this mutant is deprived of 
the lower part of the DIS stem, including the 
purine-rich internal loop that is dispensable for 
Vif binding as shown previously. In conditions 
with 200 mM KCl, the obtained ITC binding 
profile is quite similar to the one observed 
with the DIS-GAGA mutant: a slight increase 
in the stoichiometry (n = 1.2) together with a 
~2-fold drop of the affinity constant (Fig. S1 
and top). In presence of 300 mM KCl, the 
affinity decreased to 1.3 μM, highlighting 
the role of electrostatic interactions in 
the Vif/DIS U275C interaction. We also 
noticed that ITC data collected with this 
DIS mutant were rather noisy (Fig. S1 and 
top), which might suggest some aggregation 
of protein/RNA complexes. Finally, to 
evaluate a possible binding of Vif to the DIS 
stem, we used a DIS A272U/ΔG273 mutant 
(Fig. 1C). Because of the perfect 
complementarity of the eight-nucleotide 
loop, this sequence forms a 22 base-pairs 
duplex in vitro instead of a loop-loop complex (Fig. S1). In a 
buffer containing 200 mM KCl, Vif binds rather tightly to 
this sequence since we observed only a ~2-fold loss in affinity 
compared with wild-type DIS, however with a substantial 
increase in the stoichiometry (n = 1.6). As observed previously 
for the DIS U275C mutant, the Vif affinity for the DIS A272U/
ΔG273 mutant was severely affected in presence of 300 mM KCl 
(K
d
 = 0.7 μM).
It thus appears that Vif behaves quite similarly with DIS 
A272U/ΔG273 and DIS U275C, i.e., in DIS sequences where the 
7-base-pair upper part of the stem is preserved. A detailed look in 
the binding thermodynamics of the Vif-DIS A272U/ΔG273 and 
Vif-DIS U275C interactions in 200 mM KCl (Fig. S1) reveals an 
important loss in the binding enthalpy (ΔH = -5.0 and -4.3 kcal/
mol, respectively) compensated by an important gain in binding 
entropy (ΔS = 15.4 and 17.1 cal/mol/K, respectively) compared 
with binding to the wild-type DIS kissing-loop complex. This 
suggests that Vif binds the wild-type DIS and mutant sequences 
using slightly different binding mechanisms, likely mixed hydro-
phobic and electrostatic interactions on the wild-type DIS, but 
mostly electrostatic interactions in DIS loop mutants since bind-
ing is more sensitive to monovalent salt concentration.
We therefore conclude from this series of Vif/DIS experi-
ments that Vif interacts both with the DIS loop-loop helix 
and the 7-base-pair stem adjacent to the loop, but not with the 
purine-rich internal loop. An increase in salt concentration only 
moderately affects Vif binding to the DIS wild-type and DIS-Δ 
sequences, but more severely the binding to DIS-GAGA, DIS 
UC275 and DIS A272U/ΔG273 mutants, i.e., all sequences 
Figure 4. ITc profiles for the titration of hIV-1 Vif on the E. coli 23 s rRNA sarcin/Ricin Loop at 
30°c and in presence of 200 or 300 mM of Kcl. each heat burst curve is the result of a 1.5 or  
2.0 μl injection of 200 μM Vif in a 15 μM RNA solution. Data could not be fitted using binding 
models available in the Origin ITc software and are likely relevant of unspecific Vif/RNA binding.
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previously shown that some 4,5-disubstituted aminoglycoside 
antibiotics specifically and tightly bind DIS dimers through 
interactions with the loop-loop helix and stem.57,75-78 We therefore 
plan in a next future to investigate a putative interference of such 
aminoglycosides on the Vif/DIS interaction.
Materials and Methods
Expression and purification of recombinant Vif. A polymerase 
chain reaction (PCR) on the pcDNA-HVif vector encoding the 
full-length HIV-1 NL4-3 Vif protein79 was used to amplify the 
Vif gene and to insert NdeI and BamHI restriction sites at the 
extremities. The digested PCR product was then inserted between 
compounds have been reported to block the Tat/TAR interaction 
in vitro and in infected cells with inhibition constants in the low 
nanomolar-range by competing with Tat for binding to the TAR 
UCU bulge.70-73 We can therefore postulate that such compounds 
should also interfere with the binding of Vif to TAR (Fig. 6A). 
This hypothesis however remains to be tested.
Regarding the DIS RNA, our results show that Vif interacts 
both with the loop-loop helix and the 7-base-pair stem adjacent 
to the apical loop. Interestingly, it was shown that this stem is 
important for APOBEC3G binding to the viral RNA.74 An 
attractive hypothesis is therefore that Vif could compete with 
APOBEC3G for binding the DIS, thus physically excluding 
the antiviral factor from packaging (Fig. 6B). Finally, we have 
Figure 5. ITc profiles for the titration of hIV-1 Vif on the hIV-1 DIs loop-loop complex and mutant DIs sequences at 30°c and in presence of 200 or 
300 mM of Kcl. each heat burst curve is the result of a 1.5 or 2.0 μl injection of 200 μM Vif in a 15 μM RNA solution. The corrected injection heats were 
derived by integration of the ITc profiles and were fitted with a one site binding model. N/A. denotes “not applicable” since accurate values could not 
be obtained using a single site binding model.
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37°C. Data were collected on an Autoflex III MALDI-TOF mass 
spectrometer (Bruker).
Light scattering experiments. Dynamic Light Scattering (DLS) 
was performed using a Zetasizer Nano S (Malvern). Static Light 
Scattering (SLS) was performed on a Dynapro Nanostar (Wyatt 
Technology Europe). For DLS experiments, protein sample was 
adjusted to 200 μM in the buffer 50 mM MOPS, pH 6.5, 150 mM 
NaCl, 0–10% glycerol, 1 mM dithiothreitol. For SLS experiments, 
a 0.1 mg ml-1 protein concentration was used in the same buffer 
containging 5% glycerol. Sample temperature was maintained 
at 30°C. Fluctuations of the scattered intensity due to Brownian 
motions were recorded at microsecond time intervals. An autocor-
relation function was derived, thus leading to the determination of 
diffusion coefficients. Assimilating proteins in solution to spheres, 
diffusion coefficients were related to the hydrodynamic radius of 
the particles, R
h
 via the Stokes-Einstein equation:
D = k
B
T/6πηR
h
where k
B
 is the Boltzmann constant, T the temperature, η the 
solvent viscosity and D the translational diffusion coefficient. 
All experimental data were corrected for solvent viscosity using 
an AMVn automated micro viscosimeter (Anton Paar) and for 
refractive index using an Abbé refractometer. Data were analyzed 
using DLS analysis software (Malvern).
NdeI and BamHI sites into the bacterial expression plasmid 
pnEAtH80 encoding a 6-His tag followed by a thrombin 
cleavage site, leading to a Vif construct containing a 
histidine tag and a protease cleavage site fused with the 
Vif N terminus (MGS SHH HHH HSS GTG SGL VPR 
GSH-Vif). The sequence of the Vif protein used is shown 
on Supplemental Figures. These plasmids pnEAtH-
Vif were used to chemically transform E. coli Rosetta 2 
strains. Production of Vif proteins was induced in LB 
liquid medium by addition of 0.5 mM IPTG to log phase 
bacterial culture (OD 600 nm = 0.5–0.6). After 4 h at 
37°C bacteria were harvested by centrifugation at 4,000 
g during 15 min and and lysed by an overnight stirring 
at room temperature in the denaturing buffer (6 M 
guanidine Hydrochloride, 100 mM sodium phosphate, 
50 mM Tris, pH 8.0). Cellular debris were separated by 
centrifugation at 100,000 g during 1 h at 4°C and the 
cleared lysate was loaded onto a Ni-NTA agarose column. 
The column was washed with the lysis buffer and elution 
was performed by applying 25 ml of the same solution at 
decreasing pH values (pH 6.5, pH 6.0, pH 5.8, pH 5.5 
and pH 5.0). The Vif containing fractions were identified 
on a 12% SDS-PAGE, pooled and the volume was 
completed to 50 ml (~0.3 mg ml-1 of Vif ) using elution 
buffer. The protein was renaturated by successive dialysis 
for 1 h at 4°C against 500 ml of a buffer containing 
50 mM MOPS pH 6.5, 150 mM NaCl, 10% glycerol, 
1 mM dithiothreitol and decreasing guanidium chloride 
concentrations (3.0 M, 1.5 M, 0.75 M, 0.42 M, 0.21 M 
and finally 0 M). The protein was then concentrated to 
~5 mg ml-1 on an Amicon Ultra-10 and stored at -80°C. Stock 
solutions were centrifuged at 100,000 g for 1 h immediately 
prior to use. The molecular mass of the purified protein was 
checked by mass spectrometry (Calculated mass: 25,035 Da, 
Observed mass: 25,036 Da, see Fig. S3A) and the identity of 
the protein was assessed by peptide mass fingerprinting (PMF, 
see Fig. S3B). The purified protein was > 95% pure based on 
SDS-PAGE analysis (Fig. S4).
Prior measurements, Vif was dialysed in either the ITC buffer 
(50 mM MOPS pH 6.5, 200–300 mM KCl, 2 mM MgCl
2
, 
10% glycerol, 1 mM dithiothreitol) or the CD buffer [50 mM 
MOPS pH 6.5, 150 mM NaCl, 2.5% glycerol, 1 mM tris(2-
carboxyethyl)phosphine]. The protein was then concentrated to 
100 μM for CD and 150–280 μM for ITC measurements. All 
buffers were argon-degased.
Mass spectrometry. Protein samples were dialyzed against 
200 mM ammonium acetate and subsequently diluted in 1:10 
water acetonitrile (v/v) mixture acidified with 1% formic acid 
to achieve a concentration of 0.3 M. Mass spectrometry was 
performed on an ESI-TOF mass spectrometer Q-TOF micro 
(Waters, MA USA). Calibration was achieved in the positive ion 
mode, using denatured horse heart myoglobin (Sigma), using 
denatured horse heart myoglobin (Sigma). For PMF analysis, Vif 
(10 μl, 5 mg ml-1) was digested with trypsin (1 μl, 10 ng μl-1) in 
native conditions in 50 mM ammonium carbonate for 30 min at 
Figure 6. consequences of our results for Vif-RNA interactions. (A) The hIV-1 
Tat protein is known to bind the TAR lateral bulge. small molecules are known 
to prevent this binding by inhibiting the Tat binding. since Vif also recognizes 
the TAR lateral bulge, we anticipate that such Tat/TAR inhibitors could also 
prevent Vif binding to TAR. (B) scheme showing that Vif could reduce ApO-
Bec3 binding to the viral genome by competing for the DIs sequence.
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27 injections of 1.5 μl aliquots of Vif protein at 150–280 μM 
were injected (at 0.5 μl s-1) into 203 μl of RNA at 15 μM in the 
sample cell. The delay between injections was 120 sec. All ITC 
curves were analyzed using the software Origin (OriginLab). All 
data could be fitted with a single-site model. Standard free ener-
gies of binding (ΔG) were obtained using the equation
ΔG = -RT ln Ka
Entropic contributions were obtained from the relationship
ΔG = ΔH - T ΔS
In our experimental conditions, the product Ka × [RNA] × 
N, where N is the number of binding sites, was in the 0.1–1,000 
range, allowing an accurate and simultaneous determination of 
binding parameters by ITC.56 Because of a too fast Vif-RNA 
binding, it was not possible to use our recently-developed kinITC 
approach to derive kinetic parameters of binding in addition to 
thermodynamic data.85
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Circular dichroism. Vif protein sample was prepared in 
50 mM MOPS, 150 mM NaCl, 2.5% glycerol, 1 mM tris(2-
carboxyethyl)phosphine, at a concentration of 100 μM and 
diluted again in the same buffer prior to the experiment at a 
final concentration of 25 μM. Far-UV CD measurements were 
performed with a J-850 Jasco spectropolarimeter equipped with 
a Peltier temperature controller and calibrated with ammonium 
d-10 camphorsulfonate. Spectra (186–260 nm) were measured 
at 30°C, with a constant bandwidth of 1 nm and a 3–5 sec 
integration time using a quartz cell of path length 0.1 mm. 
Spectra were averaged over ten scans and corrected for buffer 
contributions. Quantitative estimations of the secondary 
structure contents were performed using Dichroweb81 and the 
reference CDSSTR database 4 containing the CD spectra of 43 
soluble proteins ranging from 190 to 240 nm..
RNA sample preparation. Chemically-synthetized wild-type 
HIV-1 subtype B 27-mer TAR RNA, HIV-1 subtype A 35-mer 
DIS RNA, 27-mer Sarcin-Ricin Loop (SRL) from the E. coli 23 S 
rRNA, as well as TAR and DIS mutant sequences were purchased 
from Integrated DNA technologies or from Dharmacon. RNA 
were purified as described in reference 82. In short, RNA was 
loaded on a Nucleopac PA-100 column (Dionex) heated at 70°C 
equilibrated in 4 M urea, 20 mM Mes [2-N(-Morpholine) eth-
ane sulfonic acid], pH 6.2 and eluted using a NaClO
4
 gradient.
DIS kissing-loop complexes were obtained as follows: RNA 
was diluted to 2 μM concentration in water, heated at 90°C 
for 5 min and then cooled on ice for 5 min. As shown previ-
ously, this protocol essentially leads to the formation of DIS 
loop-loop dimers and prevents the formation of extended duplex 
dimers.83,84 A similar protocol was performed for folding of TAR 
and SRL hairpins. DIS-A272U/ΔG273 was diluted to 60 μM 
in water, heated at 90°C for 5 min and then cooled at room 
temperature. This protocol was used in order to favor the forma-
tion of a duplex instead of hairpin monomers. Folding buffer 
(50 mM MOPS pH 6.5, 200 mM KCl, 2 mM MgCl
2
) was then 
added and RNA samples were dialysed against ITC buffer (50 
mM MOPS pH 6.5, 200–300 mM KCl, 2 mM MgCl
2
, 10% 
glycerol, 1 mM dithiothreitol) and adjusted to a final concentra-
tion of 15 μM.
Isothermal titration calorimetry (ITC). ITC measurements 
were performed on a MicroCal ITC
200
 (GE Healthcare) in ITC 
buffer containing 200 or 300 mM KCl. In a typical experiment, 
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